Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy.
Identification of the factors that regulate the immune tolerance and control the appearance of exacerbated inflammatory conditions is crucial for the development of new therapies of autoimmune diseases. Some neuropeptides and hormones have emerged as endogenous agents that participate in the regulation of the processes that ensure self-tolerance. Among them, the vasoactive intestinal peptide (VIP), a well-characterised endogenous anti-inflammatory neuropeptide, has shown therapeutic potential for a variety of immune disorders. Here we examine the latest research findings, which indicate that VIP participates in maintaining immune tolerance in two distinct ways: by regulating the balance between pro-inflammatory and anti-inflammatory factors, and by inducing the emergence of regulatory T cells with suppressive activity against autoreactive T cell effectors.
Gonzalez-Rey
Elena
E
Departamento de Bioquimica Medica y Biologia Molecular, Universidad de Sevilla, Servilla, Spain.
Anderson
Per
P
Delgado
Mario
M
D000893:Anti-Inflammatory Agents / Q000276:immunology* / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000276:immunology*; D015551:Autoimmunity / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects / Q000276:immunology; D007111:Immunity, Cellular / Q000276:immunology; D007113:Immunity, Innate / Q000276:immunology; D007166:Immunosuppressive Agents / Q000276:immunology* / Q000627:therapeutic use; D018448:Models, Immunological; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology; D014660:Vasoactive Intestinal Peptide / Q000276:immunology* / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D014660:Vasoactive Intestinal Peptide